# Daclizumab to Treat Chronic Immune Thrombocytopenia

> **NCT00049725** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 24 (—)

## Conditions studied

- Thrombocytopenia

## Interventions

- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00049725
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 24 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049725, "Daclizumab to Treat Chronic Immune Thrombocytopenia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00049725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*